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Precision medicine is a buzz word mentioned frequently in the
research world currently. Indeed, initiatives such as the UK's
100,000 genomes project are based on the premise that a better
understanding of an individual's biology and genomic profile enables
clinicians to better serve their patients. In some patients, this approach
has led to diagnosis of a rare disease and an effective treatment that
was not obvious without the genetic information. In light of these
technological advances, it seems unconscionable that “sex,” which is
probably the most obvious distinguishing characteristic in humans,
has been largely ignored in biomedical research.
Hitherto, blame for the frequent failure to translate research find-
ings in the biomedical sciences into any human benefit has focused on
issues of subjective bias, flawed experimental design, and inappropri-
ate statistical analysis, as causal factors. By contrast, little consider-
ation has been given to sex differences in either the efficacy of
existing therapeutics or the implications for their refinement. Yet it is
increasingly apparent that the long‐established practice of studying
predominantly one sex (typically males) could contribute to an
apparent failure to translate. To help rectify this problem, this editorial
outlines the rationale for a policy that requires sex to be considered as
a categorical variable in all studies submitted for publication in the
British Journal of Pharmacology. We also offer advice on how to incor-
porate this variable into an optimised experimental design.
To be clear, in this article, “sex” is defined by the genetic status
of the subject, whereas “gender” refers to the social and cultural
context. Conceptually, experimental interventions in animals, such as
castration/ovariectomy, with and without hormone replacement/
substitution, have already provided substantial information about the
importance of sex hormones on anatomical and physiological develop-
ment, as well as ensuing behavioural traits. The study of gender in
experimental animals is not possible and at present remains a clinical
experimental endeavour.2 | EVIDENCE FOR SEX DIFFERENCES THAT
AFFECT PHARMACOLOGY
Interest in sex differences in response to disease harks back as far as
Hippocrates, who noted a fever outbreak in which women were lessBr J Pharmacol. 2019;1–6. wileyonlinelibrary.com/journal/bpaffected in terms of symptoms and mortality (Hippocrates of Kos, ca.
400 BCE). The discovery of sex differences in systematic comparisons
of animals' responses to an experimental challenge is also not new. For
instance, evidence that the learning behaviour of female rats was more
variable than that of males was reported in the 1930s (McNemar &
Stone, 1932). Subsequent studies also found higher variability in the
behaviour of female rats (see, e.g., Broadhurst, 1957). A recent study
has extended these findings by studying processes involved in fear
conditioning, which clearly differ in males and females, especially
during extinction (Clark, Drummond, Hoyer, & Jacobson, 2019).
Likewise, in 1947, Boynton and Todd reported that both systolic
and diastolic blood pressures, measured in a large cohort, were higher
in young men than in young women—a finding that was later repli-
cated in dogs (Van Liere, Stickney, & Marsh, 1949).
Despite the accumulating evidence that sex leads to differences in
biology, the sex of animals used in research was rarely reported. For
instance, in Volume 1 of the British Journal of Pharmacology (and
Chemotherapy) (1946), there were 27 research papers, of which 21
did not specify the sex. In the majority of cases, both sexes were
probably used, given the large numbers of animals that were studied.
Of the remaining six papers, only one specified the use of both males
and females, three used males only, but two of these involved a study
of the testis. The remaining two papers did not specify sex but
included experiments on uterine tissue.
The higher variability of responses to experimental challenges in
females provided a perceived justification for studying only male ani-
mals, even by groups who had already noted overall sex differences
(e.g., Broadhurst, Sinha, & Singh, 1959). By 1960, attempts to reduce
variance in experimental data were driving investigators to use a single
sex, and this strategy was endorsed by a prominent textbook of Phar-
macology (Lewis, 1960). A section of that book, dealing with variability
amongst animals, included the recommendation that “[in experiments,]
animals from the same strain, of similar age, weight and sex should be
used.” Meanwhile, in the clinical world, evidence was emerging that
thalidomide causes congenital abnormalities in humans. This led to
the preferential study of males in order to avoid the risk of exposing
young women to novel drugs in clinical trials.
By the late 1970s, it was clear that a wide range of physiological
systems were affected by sex differences (circadian rhythms, feeding,
the effects of localised lesion of brain regions, sensory systems, e.g.,
Beatty, 1979). There was further evidence that the profile of these© 2019 The British Pharmacological Societyh 1
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development. Despite these reports, a strong rationale for studying
males, but not females, was entrenched in both clinical and preclinical
experiments, albeit for different reasons. Exceptions to this practice
included studies using large animals, especially non‐human primates,
where data from both sexes were pooled (e.g., Yanagita & Takahashi,
1970). However, that approach was probably motivated by the need
to avoid unacceptable waste of animals, as much as to study the drug
response in a group of “typical” subjects sampled from a population.
Sex differences have now been described in all major fields of
pathology, physiology, and pharmacology in humans and experimental
animals. For instance, it is now recognised that sex differences in
ischaemic heart disease result in disparities in treatment outcome as
well as increased morbidity and mortality in women post‐myocardial
infarction (Aggarwal et al., 2018). Another large cohort study, the
European Prospective Investigation into Cancer and Nutrition (EPIC),
has reported sex differences in the prevalence of certain diet‐related
cancers (Zamora‐Ros et al., 2018); these could be attributed to differ-
ences in the activity of metabolic enzymes in men and women (e.g.,
Dellinger, Garcia, & Meyskens, 2014). There are numerous reports of
sex differences in the responses to inflammatory stimuli in experimen-
tal animals, a finding confirmed in two studies of healthy volunteers
(Rathod et al., 2017), and a recent report indicates genetically depen-
dent sex differences in the incidence of irritable bowel syndrome
(Bonfiglio et al., 2018). These few examples of the differences in
healthy volunteers and patients provide a strong rationale for the con-
sideration of sex when investigating pathways of disease, identifying
novel targets and teasing out the pharmacology of novel therapeutics.
There is now tangible evidence for a growing appreciation within
the research community that sex/gender research is important. For
instance, a PubMed search of the term “sex difference” in 2018
identifies 41 reviews. In particular, the growth of sex/gender research
in pharmacology has stimulated the commissioning of a BJP Themed
Issue on this topic in 2019. In this themed issue alone, there are
reviews and original articles demonstrating that sex is an important
determinant of physiology, disease phenotype, and drug response
from diverse systems of the body spanning across schizophrenia
(Gogos, Ney, Seymour, Van Rheenen, & Felmingham, 2019), fear sen-
sation (Clark et al., 2019) to metabolism (Henstridge, Abildgaard,
Lindegaard, & Febbraio, 2019) and obesity (Taylor, Ramirez, Musail,
& Sullivan, 2019). A focus upon sex driving diversity in drug response
is also evident from the literature: Recent examples include that air-
way smooth muscle, isolated from obese females, manifests greater
agonist‐induced excitation–contraction coupling than those derived
from lean males, females, or from obese males (Orfanos et al., 2018)
and that sex differences in the thermoregulatory and behavioural
responses to the CNS stimulant, cathinone (Alsufyani & Docherty,
2017), have been identified. However, a notable complication is that
the response of interest can depend on an interaction between sex
and genotype, as was the case for the vulnerability to obesity in a
strain of genetically altered mice (Pillidge, Heal, & Stanford, 2016).
Unlike the BJP of 1946, sex is mentioned in the BJP of today. Of 27
consecutive original articles (published in Vol 176 issue 3–7), 22 wereanimal studies of which 19 reported the sex of the animals used,
which is a substantial improvement. However, of these 19, 12 used
only males and five used only females. There were also six studies
using human tissues (tissue, blood, or cell culture) of which two
specified a female source. Cell culture and cell lines were used in 16
studies, of which two cell cultures were described as being derived
from females. None of the studies compared sexes. We contend that
whilst the reporting of sex in BJP is encouraging, it is not enough to
state the sex of the animals used, and so, to improve our practices
further, we encourage researchers to study both sexes.3 | REASONS FOR STUDYING BOTH MALES
AND FEMALES
Arguably, the most important reason to study both sexes is to facili-
tate successful translation of science with goals that improve human
well‐being, regardless of sex. It should be obvious that translation of
encouraging preclinical findings with new molecular entities, or even
repurposing of drugs, risks failure if the supporting evidence is based
on research using males only.
Furthermore, substantial evidence shows that the stage of
oestrous/menstrual cycle, not just sex, can affect the response to
drugs (e.g., in cardiac electrophysiology; see Salama & Bett, 2014).
Such findings underpin the conventional view that responses of
females to experimental challenges are more variable than males. It
should be acknowledged that this concept has been challenged
recently following a meta‐analysis of a wide range of studies of both
mice (Prendergast, Onishi, & Zucker, 2014) and rats (Becker,
Prendergast, & Liang, 2016), which led to the conclusion that “intrinsic
variability … is at least as great in males as variability associated with
the females estrous cycle.” Nevertheless, the potential problems that
could arise from studying only males, when the intention is to extrap-
olate the findings to the whole population, are obvious.
Perhaps the new experimental environment will stimulate much‐
needed, systematic studies of the effects of the oestrous cycle on drug
actions. In the meantime, it is widely agreed that the problem of sex
differences in response to an experimental challenge can no longer
be ignored, to the extent that some national funding agencies such
as the National Institutes of Health (NIH) (USA) and the Swedish
Research Council are now requiring consideration of sex and/or
gender in all applications. Importantly, this mandate includes cells
maintained in vitro, not just whole animals (https://orwh.od.nih.gov/
sex‐gender/nih‐policy‐sex‐biological‐variable). This aspect is critical
since, for instance, electrophysiological studies of isolated cardiac
muscle cells (Lu et al., 2006) can be used to assess the propensity of
drugs to cause the ventricular arrhythmia of Torsade de Pointes
(Cubeddu, 2003), which is more common in females. There is also
evidence for sex differences even at the level of individual
cardiomyocytes (Mason & MacLeod, 2009; Salama & Bett, 2014).
Importantly, it is not common practice for authors to state the sex of
the individual (human or animal) from which primary cells have been
derived (particularly if these cells have been purchased) and rare for
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ous exceptions of cell lines such as the Chinese hamster ovary (CHO).
Another important justification for studying both sexes is to
address concerns regarding the ethical burden of surplus breeding. In
the UK alone, 1.81 million non‐genetically altered animals (91% of
which were mice or rats) were bred for scientific procedures in 2017
but were killed, or died, without being used in any regulated procedure
(Gov.uk, 2018). Some of these animals would have been used for
collecting tissue for studies post mortem, but many would have been
surplus stock and much of this surplus would comprise female animals.
This attrition should be taken into account when considering compli-
ance with the 3Rs (Replacement, Reduction, Refinement), notably in
respect of Reduction (Russell & Burch, 1959).4 | BJP POLICY
The British Journal of Pharmacology has decided to rectify this neglect
of sex as a research variable, and we recommend that all future studies
published in this journal should acknowledge consideration of the
issue of sex. In the ideal scenario for in vivo studies, both sexes will
be included in the experimental design. However, if the researcher's
view is that sex or gender is not relevant to the experimental question,
then a statement providing a rationale for this view will be required.
Obvious examples of this would include studies of reproduction,
genitalia, the actions of sex hormones, or sex‐specific diseases and
the use of immortalised cell lines. An example of an article in a recent
issue of this journal where details of the numbers of each sex of the
animals that were used for each stage of the study were given is Clark
et al. (2019).
We acknowledge that the economics of investigating the influence
of sex on experimental outcomes will be difficult until research grant‐
funding agencies insist that researchers adapt their experimental
designs, in order to accommodate sex as an experimental variable
and provide the necessary resources. In the meantime, manuscripts
based on studies that have used only one sex or gender will continue
to be published in BJP. However, we will require authors to include a
statement to justify a decision to study only one sex or gender. In such
cases, the conclusions should be expressed cautiously; if only males
were used in the experiment, there should be an explicit statement
to the effect that findings from the work might not be replicated in
females.
Even once funding agencies have amended their approach, articles
based on fundamental studies of pharmacological targets in vitro (such
as receptors and enzymes), in single cell lines, will still be considered
for publication in BJP, but we would need experimental confirmation
that any findings from primary cells that underpin the main conclusion
have been replicated in both sexes, unless there is an explicit justifica-
tion for not doing so.
We shall review and revise this policy continually, to ensure it
remains consistent with that of research funders as they move
towards the mandatory study of both sexes.5 | IMPLICATIONS FOR THE DESIGN AND
STATISTICAL ANALYSIS OF STUDIES USING
BOTH SEXES
To support researchers, we offer some considerations, below, that
might help when designing future experiments.5.1 | Implications for parametric analysis
In the light of evidence, albeit now controversial, that sex can influ-
ence the variability of the response of interest, authors should ensure
that the data from studies using both sexes comply with the homoge-
neity of variance assumption that must be met for valid use of para-
metric statistics. The need to comply with this assumption, even for
simple experimental designs, is explained in Curtis et al. (2018). A
suitable transformation of the data (e.g., logarithm or square root)
should be applied to the responses, if necessary, before carrying out
any parametric analysis.5.2 | Randomisation
Overall sex differences and, more importantly, interactions between
experimental interventions and sex (i.e., the effect of the intervention
differs in the two sexes) cannot be inferred if males and females are
studied in separate time frames. It is not correct for animals from both
sexes to be fully randomised within the study. If animals are
randomised across treatment interventions, then this could lead to
an unequal replication of males versus females across all the treatment
groups. If there are overall differences between males and females,
then this imbalance will bias the treatment comparisons. The
technique of “blocking” or stratification must be used so that each
treatment group is replicated equally often in both sexes, that is,
randomise what looks like a mini‐study in each sex.
Another example is when the study is to be carried out, at inter-
vals, over a long period of time, with each subject being tested only
once. In such cases, it would be more appropriate to treat both “day”
and “sex” as blocking factors, that is, for equal numbers of male and
female subjects to be tested, in parallel, on each day. The distribution
of the different levels of the experimental factor (e.g., drug treatment)
should be the same for both sexes, within each block, but randomised
or counterbalanced (as in a Williams Latin Square) over the whole
series of test days.
In conscious animal experiments, a potential confounder is that the
response of interest might be affected by the close proximity of an
animal of the opposite sex. We have no specific recommendation on
how to deal with this, and it should be borne in mind that this situation
will replicate their “real world.” We ask authors merely to consider
whether or not males and females should be physically separated, to
ensure that sight and smell are not an issue that could confound the
results, and to report on how this was addressed when carrying out
the study. Obviously, it would not be advisable to house males and
females in different rooms because that would undermine the need
4 EDITORIALBJPfor the animals to be exposed to the same environmental factors in a
properly controlled experiment.5.3 | Blinding
When carrying out studies in vivo, it can be difficult for experimenters
to be blind to the sex of the animal. Nevertheless, as is currently the
policy for this journal, blinding for this factor should be in place when-
ever possible. For example, samples can be coded and the order of
processing them can be randomised after taking them from the
animals. There should also be blinding during the statistical analysis
of the data, as is the case for all other factors. However, blinding at
this late stage will not resolve problems arising from any subjective
bias that has been introduced during earlier stages of the experiment.5.4 | Approaches to experimental design to enable
consideration of sex
An inevitable consequence of studying both sexes is that each study
will need more animals than would be necessary if only a single sex
is used. However, by adopting a factorial design, with “Sex” and
“Treatment” (e.g., a range of different test drugs or doses) as the
experimental factors, a relatively small number of animals of each
sex can provide sufficient information on the overall effect of the
experimental factors.
If the objectives of the experiment rest on comparing specific pairs
of treatment group means, from experiments with a factorial design,
using a post hoc test (e.g., male vs. female at a specific test drug dose,
or a specific test drug vs. vehicle for a single sex) then, to comply with
this journal's rubric, sample sizes must be N ≥ 5 for each combination
of Sex and Treatment. It follows that an experiment investigating the
effects of three drug doses (or three different drugs) plus vehicle, in
both sexes (with each animal receiving only one treatment), would
need a total of at least 40 animals (see Table 1).
However, using a factorial experimental design and two‐way
ANOVA to analyse the data implies that information from the raw
data will be shared across all the factor levels. As a consequence, the
40‐animal design risks wasting animals if the impact of Sex upon theTABLE 1 Showing the total number of animals for each of the
experimental factors, Sex and Treatment, when five different animals
(i.e., N = 5) are assigned to each combination of these two factors
Factor 2: Treatment
(e.g., different compounds
or doses)
Factor 1: Sex
Male Female Total
Vehicle 5 5 10
Drug A or low dose 5 5 10
Drug B or intermediate dose 5 5 10
Drug C or high dose 5 5 10
Total 20 20 40measured variable was not a primary outcome measure of the study,
which would compromise Reduction (as in Russell & Burch, 1959).
This is especially likely to arise when the objective of the experiment
is solely to test whether “Treatment” (across a range of test groups
of drugs or doses) has an overall effect on the variable of interest.
However, in this article, we are arguing that, for preclinical research
to be more representative of the human setting, both sexes should
be incorporated into the experimental design. In such cases, where
the impact of sex on a specific treatment is not one of the experimen-
tal outcomes being interrogated, then we suggest that using only three
animals for each combination of factors can sometimes be adequate.
This is because equal numbers of males and females for each combina-
tion of Sex and Treatment yields a total of six animals for each level of
Treatment. Providing that there is no evidence for an interaction
between the two factors, which would be evident from the ANOVA
analysis, then it is valid to combine the data from the two sexes and
proceed with an analysis of any main effect of Treatment.
This scenario illustrates the importance of prospective definition of
the experimental objective(s) and careful planning of the experimental
design, which should include a sample size estimation that is
documented in the manuscript.
For more advice and information on this topic, see: Bate and Clark
(2014); Percie du Sert et al. (2017); the NC3Rs Experimental Design
Assistant (https://www.nc3rs.org.uk/experimental‐designassistant‐eda);
Festing et al. (2016).
5.5 | The oestrous cycle
Unless the objective of the study is specifically to investigate drug‐
induced responses at specific stages of the oestrous cycle, we shall
not require authors to record or report this information in this journal.
This is not least because procedures to determine oestrous status are
moderately stressful and an interaction between the stress response
and stage of the oestrous cycle could affect the experimental out-
come. However, authors should be aware that the stage of the
oestrous cycle may affect response to drugs particularly in behavioural
studies, as reported for actions of cocaine in rats and mice (Calipari
et al., 2017; Nicolas et al., 2019).6 | SUMMARY
• BJP now requires sex to be considered as an experimental variable
for all experimental reporting. This will affect the details of the
experimental design that are documented or, in the absence of a
design incorporating both sexes, a full justification for that approach.
• We recommend that all experiments (in vitro, in vivo, and ex vivo)
should include both sexes, unless there is a specific justification
or exemption, such as when using immortalised cell lines or tissue
derived from a sex organ.
• Multifactorial designs should be used to study the overall effects of
Sex, Treatment (i.e., the experimental intervention), and their
interaction.
EDITORIAL 5BJP• Authors should consider the implications for the study findings
when testing males and females in close proximity, particularly in
behavioural studies, and describe these implications in the discus-
sion of the manuscript.
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